Single-dose Daclizumab Induction Therapy in Patients with Liver Transplantation

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2003 Aug 15

PMID 12918145

Citations 1

Authors

Lu-Nan Yan

Wei Wang

Bo Li

Shi-Chun Lu

Tian-Fu Wen

Qi-Yuan Lin

Yong Zeng

Nan-Sheng Cheng

Ji-Chun Zhao

Yue-Meng Dai

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).

Methods: A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.

Results: Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.

Conclusion: Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.

Citing Articles

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.

Mullen J, Kuurstra E, Oreopoulos A, Bentley M, Wang S Transplant Res. 2014; 3:14.

PMID: 25093077 PMC: 4120716. DOI: 10.1186/2047-1440-3-14.

References

Wu M, Shu K, Cheng C, Chen C, Lian J . MMF-based regimen in maintenance therapy after kidney transplantation. Transplant Proc. 2000; 32(7):1748-50. DOI: 10.1016/s0041-1345(00)01392-0. View

Levy G . Neoral is superior to FK 506 in liver transplantation. Transplant Proc. 1998; 30(5):1812-5. DOI: 10.1016/s0041-1345(98)00442-4. View

Light J, Sasaki T, Ghasemian R, Barhyte D, Fowlkes D . Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant. 2002; 16 Suppl 7:30-3. DOI: 10.1034/j.1399-0012.16.s7.4.x. View

Calmus Y, Scheele J, Gonzalez-Pinto I, Jaurrieta E, Klar E, Pageaux G . Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002; 8(2):123-31. DOI: 10.1053/jlts.2002.30882. View

Koch M, Niemeyer G, Patel I, Light S, Nashan B . Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation. 2002; 73(10):1640-6. DOI: 10.1097/00007890-200205270-00020. View

Ahmad S, Stegman Z, Fructhman S, Asbell P . Successful treatment of acute ocular graft-versus-host disease with tacrolimus (FK506). Cornea. 2002; 21(4):432-3. DOI: 10.1097/00003226-200205000-00024. View

Vincenti F, Jensik S, Filo R, Miller J, Pirsch J . A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002; 73(5):775-82. DOI: 10.1097/00007890-200203150-00021. View

Lerut J, Ciccarelli O, Mauel E, Gheerardhyn R, Talpe S, Sempoux C . Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study. Transpl Int. 2002; 14(6):420-8. DOI: 10.1007/s001470100008. View

Boggi U, Vistoli F, Coppelli A, Marchetti P, Rizzo G, Mosca F . Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. Transplant Proc. 2001; 33(7-8):3201-2. DOI: 10.1016/s0041-1345(01)02362-4. View

10.

Krueger J, Walters I, Miyazawa M, Gilleaudeau P, Hakimi J, LIGHT S . Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000; 43(3):448-58. DOI: 10.1067/mjd.2000.106515. View

11.

Ciancio G, Burke G, Miller J . Current treatment practice in immunosuppression. Expert Opin Pharmacother. 2001; 1(7):1307-30. DOI: 10.1517/14656566.1.7.1307. View

12.

Ramji A, Yoshida E, Bain V, Kneteman N, Scudamore C, Ma M . Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl. 2002; 8(10):945-51. DOI: 10.1053/jlts.2002.34969. View

13.

Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O . Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2(1):48-56. DOI: 10.1034/j.1600-6143.2002.020109.x. View

14.

Kwekkeboom J, Zondervan P, Kuijpers M, Tilanus H, Metselaar H . Fine-needle aspiration cytology in the diagnosis of acute rejection after liver transplantation. Br J Surg. 2003; 90(2):246-7. DOI: 10.1002/bjs.4099. View

15.

Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K . A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003; 98(2):369-76. DOI: 10.1111/j.1572-0241.2003.07239.x. View

16.

Meier-Kriesche H, Kaplan B . Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant. 2002; 2(1):100-4. DOI: 10.1034/j.1600-6143.2002.020116.x. View

17.

Ankersmit H, Roth G, Zuckermann A, Moser B, Obermaier R, Taghavi S . Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. Am J Transplant. 2003; 3(2):231-4. DOI: 10.1034/j.1600-6143.2003.00030.x. View

18.

Eckhoff D, McGuire B, Sellers M, Contreras J, Frenette L, Young C . The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000; 69(9):1867-72. DOI: 10.1097/00007890-200005150-00022. View

19.

Kato T, Sato Y, Kurasaki I, Yamamoto S, Hirano K, Nakatsuka H . FK506 may suppress liver injury during the early period following living-related liver transplantation. Transplant Proc. 2003; 35(1):79. DOI: 10.1016/s0041-1345(02)03862-9. View

20.

Vincenti F, Kirkman R, LIGHT S, Bumgardner G, Pescovitz M, Halloran P . Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998; 338(3):161-5. DOI: 10.1056/NEJM199801153380304. View